An antiplatelet drug (antiaggregant), also known as platelet agglutination inhibitor or platelet aggregation inhibitor, is a member of a class of pharmaceuticals that reduces platelet aggregation and hinder thrombus formation. Antiplatelet drugs can reversibly or irreversibly inhibit the process involved in platelet activation, resulting in decreased tendency of platelets to adhere to one another and to endothelium of damaged blood vessels. They are widely used in primary and secondary prevention of thrombotic cerebrovascular or cardiovascular disease. Antiplatelet therapy with one or more of these drugs decreases the ability of blood clot formation by interfering with the platelet activation process in primary hemostasis. They are useful in arterial circulation, where anticoagulants have lesser effect. 

Market scope and structure analysis:

COVID-19 scenario analysis:

Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak. This is carried out by supporting development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have seen huge boost in demand for management of COVID-19. There is an increase in demand for the drug, which has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of the drug. Hence, owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

Surge in ageing population is the major factor that propels the antiplatelet market growth. Furthermore, proliferation of antithrombotic/anticoagulant drugs would also help the industry gain traction during the forecast period. Surge in thrombotic events is also anticipated to fuel growth of the industry. Moreover, advancements in the antiplatelet market are expected to help the industry acquire higher revenue in the coming years.

Growth in number of product launches to boost the market

Growth in number of product launches would help the industry flourish in the forecast period. For instance, in June 2020, Medtronic plc, the global leader in medical technology, announced it had received CE (Conformité Européenne) Mark for a one-month dual antiplatelet therapy (DAPT) indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx Drug-Eluting Stent (DES). For HBR patients, whose bleeding risk may be increased by taking longer DAPT regimens (a combination of aspirin and anti-clotting medication), this new, first-of-its-kind indication allows physicians to recommend a shorter, one-month regimen of DAPT, following a percutaneous coronary intervention (PCI) with Resolute Onyx.

The approval is the first of its kind globally. Resolute Onyx DES is available for use in the U.S., as well as in Europe and other countries that recognize the CE Mark. Resolute Onyx DES is not currently indicated for HBR patients with one-month DAPT in the U.S. Data have been submitted to the FDA with the intent to obtain a one-month DAPT US Indication for Resolute Onyx DES.

Surge in number of mergers and acquisitions to propel the market

Increase in number of mergers and acquisitions is anticipated to help the industry grow in the coming years. For instance, in September 2020, Mylan planned a megamerger with Pfizer's Upjohn generics unit has had a rocky road to approval, with the novel coronavirus pandemic snagging regulatory review.. Mylan is expected shell out $756 million for European rights to a suite of Aspen Pharmacare's sterile injectable anticoagulants that raked in nearly a quarter-billion dollars in the year ending June 30, the generics giant said Tuesday.

Mylan is expected pay Aspen $310 million in cash upfront with an additional cash payment of $446 million due by June 25, 2021. The deal is expected to close by December 31, roughly in line with the closing date for Mylan's planned merger with Pfizer's Upjohn generics unit.

Key segments covered:

Key benefits of the report:

• This study presents the analytical depiction of the global antiplatelet industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global antiplatelet market share.
• The current market is quantitatively analyzed from 2020 to 2027 to highlight the global antiplatelet market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the antiplatelet market.
• The report provides a detailed global antiplatelet market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the antiplatelet market research report:

• Which are the leading market players active in the antiplatelet market?
• What would be the detailed impact of COVID-19 on the antiplatelet market?
• What current trends would influence the antiplatelet market in the next few years?
• What are the driving factors, restraints, and opportunities in the antiplatelet market?

• What are the projections for the future that would help in taking further strategic steps?